amyloid-beta-peptides and morin

amyloid-beta-peptides has been researched along with morin* in 2 studies

Other Studies

2 other study(ies) available for amyloid-beta-peptides and morin

ArticleYear
Morin inhibits the early stages of amyloid β-peptide aggregation by altering tertiary and quaternary interactions to produce "off-pathway" structures.
    Biochemistry, 2012, Jul-31, Volume: 51, Issue:30

    Alzheimer's disease is a debilitating neurodegenerative disorder whose pathology has been linked to the aggregation and deposition of the amyloid β-peptide (Aβ) in neural tissue. A truly effective therapeutic agent remains elusive, and attention has recently turned to the use of natural products as effective antiaggregation compounds, directly targeting Aβ. Although a wealth of in vitro and in vivo evidence suggests these compounds or their derivatives might be beneficial, a detailed understanding of the mechanism by which they act remains largely unknown. Using atomistic, explicit-solvent molecular dynamics simulations, we have investigated the association of the flavonoid morin with Aβ monomers and dimers. Through 90 simulations totaling 23.65 μs, we found that treatment of Aβ peptides with morin largely does not affect secondary structure content, unless a large molar excess of morin is present. However, in simulations of Aβ monomers and dimers, morin affected the tertiary and quaternary structure of Aβ, even at low concentrations that have been used experimentally. Thus it appears that despite the inability of morin to fully block Aβ aggregation or β-strand formation, we observe structures with altered tertiary and quaternary interactions, which may represent "off-pathway" aggregates that have been proposed previously. The simulations presented here add important new details to the mechanism of these processes.

    Topics: Amyloid beta-Peptides; Antioxidants; Flavonoids; Humans; Peptide Fragments; Protein Structure, Quaternary; Protein Structure, Tertiary; Signal Transduction

2012
Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease.
    Journal of neurochemistry, 2003, Volume: 87, Issue:1

    Cerebral deposition of amyloid beta-peptide (Abeta) in the brain is an invariant feature of Alzheimer's disease (AD). A consistent protective effect of wine consumption on AD has been documented by epidemiological studies. In the present study, we used fluorescence spectroscopy with thioflavin T and electron microscopy to examine the effects of wine-related polyphenols (myricetin, morin, quercetin, kaempferol (+)-catechin and (-)-epicatechin) on the formation, extension, and destabilization of beta-amyloid fibrils (fAbeta) at pH 7.5 at 37 degrees C in vitro. All examined polyphenols dose-dependently inhibited formation of fAbeta from fresh Abeta(1-40) and Abeta(1-42), as well as their extension. Moreover, these polyphenols dose-dependently destabilized preformed fAbetas. The overall activity of the molecules examined was in the order of: myricetin = morin = quercetin > kaempferol > (+)-catechin = (-)-epicatechin. The effective concentrations (EC50) of myricetin, morin and quercetin for the formation, extension and destabilization of fAbetas were in the order of 0.1-1 micro m. In cell culture experiments, myricetin-treated fAbeta were suggested to be less toxic than intact fAbeta, as demonstrated by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. Although the mechanisms by which these polyphenols inhibit fAbeta formation from Abeta, and destabilize pre-formed fAbetain vitro are still unclear, polyphenols could be a key molecule for the development of preventives and therapeutics for AD.

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Flavonoids; Humans; Kidney; Kinetics; Microscopy, Electron; Peptide Fragments; Phenols; Polymers; Quercetin; Spectrometry, Fluorescence; Tetrazolium Salts; Thiazoles

2003